Ampersand Capital Partners is a middle-market private equity group that concentrates on growth equity investment opportunities in the healthcare sector. The Firm looks to invest $10 to $30 million in businesses with $10 to $100 million of revenue. Specific areas of interests within healthcare include lab products, specialty diagnostic equipment, pharmaceutical outsourcing, and specialty pharma. Ampersand generally prefers to be the first and sole institutional investor. Ampersand was formed in 1988 and is based in Wellesley, Massachusetts.
Join Mergr to view the latest updates and news from Boston-based Ampersand Capital Partners.
In the last 3 years, Ampersand Capital Partners has acquired 3 companies. It has also invested in 5 others.
Ampersand Capital Partners’ most common sectors for investment are life science (38%) and medical products (30%). The Firm’s most common investment types include buyout (lbo, mbo, mbi) (35%) and growth capital (25%). In total, Ampersand Capital Partners has invested in 19 US states. Its largest (disclosed) acquisition occurred in 2013 when it acquired BioClinica for $123M.
In the last 3 years, Ampersand Capital Partners has exited 9 companies. The Firm’s most common exit type is trade sale (74%). Ampersand Capital Partners’ largest (disclosed) exit occurred in 2008 when it sold Talecris Biotherapeutics Holdings Corp for $3.1B.
Join Mergr to view Ampersand Capital Partners’ full profile and discover more large private equity firms just like it.
No obligation. Cancel anytime.